Deleted in liver cancer-1 inhibits the proliferation and invasion of enzalutamide-resistant prostate cancer cells via the Rho pathway

Tang Yangbin; Yang Guo; Wu Xiaohou; Quan Zhen

doi:10.13406/j.cnki.cyxb.003595

您当前的位置：

首页 >

文章列表页 >

Deleted in liver cancer-1 inhibits the proliferation and invasion of enzalutamide-resistant prostate cancer cells via the Rho pathway

Basic research | 更新时间：2025-10-23

- Deleted in liver cancer-1 inhibits the proliferation and invasion of enzalutamide-resistant prostate cancer cells via the Rho pathway
- Journal of Chongqing Medical University Vol. 49, Issue 10, Pages: 1061-1066(2024)
- 作者机构：
  
  重庆医科大学附属第一医院泌尿外科，重庆 421800
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003595
  CLC： R737.25
- Received：14 March 2024，
  
  Revised：2024-05-06，
  
  Accepted：13 May 2024，
  
  Published：28 October 2024
- 稿件说明：
移动端阅览
汤洋斌,杨果,吴小候,等.DLC-1通过Rho通路抑制耐恩杂鲁胺前列腺癌细胞的增殖与侵袭能力[J].重庆医科大学学报,2024,49(10):1061-1066.

Tang Yangbin,Yang Guo,Wu Xiaohou,et al.Deleted in liver cancer-1 inhibits the proliferation and invasion of enzalutamide-resistant prostate cancer cells via the Rho pathway[J].Journal of Chongqing Medical University,2024,49(10):1061-1066.
汤洋斌,杨果,吴小候,等.DLC-1通过Rho通路抑制耐恩杂鲁胺前列腺癌细胞的增殖与侵袭能力[J].重庆医科大学学报,2024,49(10):1061-1066. DOI： 10.13406/j.cnki.cyxb.003595.

Tang Yangbin,Yang Guo,Wu Xiaohou,et al.Deleted in liver cancer-1 inhibits the proliferation and invasion of enzalutamide-resistant prostate cancer cells via the Rho pathway[J].Journal of Chongqing Medical University,2024,49(10):1061-1066. DOI： 10.13406/j.cnki.cyxb.003595.

摘要

目的

探索肝癌缺失因子1（deleted in liver cancer 1，DLC-1）对耐恩杂鲁胺前列腺癌（prostate cancer，PCa）细胞增殖，侵袭和凋亡的影响以及作用机制。

方法

体外以不同浓度的恩杂鲁胺药物培养人前列腺癌lncap及C4-2细胞株6个月以上，构建恩杂鲁胺耐药细胞系lncap-R，C4-2-R。CCK-8法检测其IC

，验证恩杂鲁胺耐药株是否构建成功。利用慢病毒转染lncap-R，C4-2-R，以敲低和过表达DLC-1，采用克隆实验、Transwell实验和流式细胞术检测DLC-1对耐恩杂鲁胺的前列腺癌细胞的增殖、侵袭和凋亡的影响。

结果

与对照组相比，过表达组DLC-1显著抑制了2个耐药株的增殖和侵袭进程。机制上，WB实验结果表明DLC-1表达与2个耐药株中Rho蛋白的表达呈负相关。Rho抑制剂rhosin逆转了因敲低DLC-1后lncap-R细胞凋亡减少的情况。

结论

DLC-1可以下调耐药株中的Rho蛋白的表达，并抑制耐药株的增殖和侵袭。

Abstract

Objective

To investigate the effect of deleted in liver cancer-1（DLC-1） on the proliferation，invasion，and apoptosis of enzalutamide-resistant prostate cancer cells and its mechanism of action.

Methods

Hμmol/Lan prostate cancer lncap and C4-2 cell lines were cultured

in vitro

with different concentrations of enzalutamide for more than 6 months，and enzalutamide-resistant cell lines were co

nstructed as lncap-R and C4-2-R. IC

was measured by CCK-8 assay to verify the successful construction of enzalutamide-resistant cell lines. lncap-R and C4-2-R were transfected by lentivirus to achieve the knockdown and overexpression of DLC-1，and colony formation assay，Transwell assay，and flow cytometry were used to observe the effect of DLC-1 on the proliferation，invasion，and apoptosis of enzalutamide-resistant prostate cancer cells.

Results

Compared with the control group，the overexpression group showed that DLC-1 significantly inhibited the proliferation and invasion of the two enzalutamide-resistant cell lines. As for mechanism of action，Western blot showed that the expression of DLC-1 was negatively correlated with the expression of Rho protein in both enzalutamide-resistant cell lines. The Rho inhibitor rhosin reversed the reduction in the apoptosis of lncap-R cells due to knockdown of DLC-1.

Conclusion

DLC-1 can downregulate the expression of Rho protein in drug-resistant cell lines and inhibit their proliferation and invasion.

关键词

Keywords

references

Siegel DA ， O’Neil ME ， Richards TB ， et al . Prostate cancer incidence and survival，by stage and race/ethnicity - United States，2001-2017 [J ] . MMWR Morb Mortal Wkly Rep ， 2020 ， 69 （ 41 ）： 1473 - 1480 ．

Zhou ZE ， Xu YY ， Li QY ， et al . Prognostic significance of a novel indicator （PSA postd3 /PSA pre ）for PSA recurrence in patients after radical prostatectomy [J ] . Cancer Manag Res ， 2019 ， 11 ： 5777 - 5783 ．

Schmidt-Hegemann NS ， Zamboglou C ， Mason M ， et al . ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer [J ] . Radiother Oncol ， 2023 ， 183 ： 109544 ．

Liu PY ， Wang WX ， Wang F ， et al . Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer [J ] . J Transl Med ， 2023 ， 21 （ 1 ）： 40 ．

Cheng Q ， Butler W ， Zhou YL ， et al . Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy [J ] . Eur Urol ， 2022 ， 81 （ 5 ）： 446 - 455 ．

Agarwal N ， Azad AA ， Carles J ， et al . Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer （TALAPRO-2）：a randomised，placebo-controlled，phase 3 trial [J ] . Lancet ， 2023 ， 402 （ 10398 ）： 291 - 303 ．

Armstrong AJ ， Iguchi T ， Azad AA ， et al . The efficacy of enzalutamide plus androgen deprivation therapy in oligometastatic Hormone-sensitive prostate cancer：a post hoc analysis of Arches [J ] . Eur Urol ， 2023 ， 84 （ 2 ）： 229 - 241 ．

Han H ， Wang Y ， Curto J ， et al . Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis [J ] . Cell Rep ， 2022 ， 39 （ 1 ）： 110595 ．

Wang JX ， Zeng LL ， Wu NS ， et al . Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells [J ] . Drug Resist Updat ， 2023 ， 70 ： 100985 ．

Basak P ， Dillon R ， Leslie H ， et al . The Deleted in Liver Cancer 1 （Dlc1） tμmol/Lor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity [J ] . BMC Cancer ， 2015 ， 15 ： 630 ．

Liao YC ， Lo SH . Deleted in liver cancer-1 （DLC-1）：a tμmol/Lor suppressor not just for liver [J ] . Int J Biochem Cell Biol ， 2008 ， 40 （ 5 ）： 843 - 847 ．

Ren GH ， Li GR . Tμmol/Lor suppressor gene DLC1：its modifications，interactive molecules，and potential prospects for clinical cancer application [J ] . Int J Biol Macromol ， 2021 ， 182 ： 264 - 275 ．

Niu N ， Ma XJ ， Liu HT ， et al . DLC1 inhibits lung adenocarcinoma cell proliferation，migration and invasion via regulating MAPK signaling pathway [J ] . Exp Lung Res ， 2021 ， 47 （ 4 ）： 173 - 182 ．

Mosaddeghzadeh N ， Ahmadian MR . The RHO family GTPases：mechanisms of regulation and signaling [J ] . Cells ， 2021 ， 10 （ 7 ）： 1831 ．

Nguyen-Nielsen M ， Borre M . Diagnostic and therapeutic strategies for prostate cancer [J ] . Semin Nucl Med ， 2016 ， 46 （ 6 ）： 484 - 490 ．

Alajati A ， D’Ambrosio M ， Troiani M ， et al . CDCP1 overexpression drives prostate canc er progression and can be targeted in vivo [J ] . J Clin Invest ， 2020 ， 130 （ 5 ）： 2435 - 2450 ．

Alyamani M ， Li J ， Patel M ， et al . Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure [J ] . Ann Oncol ， 2020 ， 31 （ 3 ）： 369 - 376 ．

Bultijnck R ， Deforche B ， Borrey N ， et al . Exercise prescription dose for castrate-resistant prostate cancer patients：a phase I prescription dose escalation trial [J ] . World J Urol ， 2021 ， 39 （ 2 ）： 357 - 364 ．

Cerasuolo M ， Maccarinelli F ， Coltrini D ， et al . Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer [J ] . Cancer Res ， 2020 ， 80 （ 7 ）： 1564 - 1577 ．

Chen XL ， Liu JH ， Cheng LJ ， et al . Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer [J ] . Prostate ， 2020 ， 80 （ 3 ）： 256 - 266 ．

Dai C ， Heemers H ， Sharifi N . Androgen signaling in prostate cancer [J ] . Cold Spring Harb Perspect Med ， 2017 ， 7 （ 9 ）： a030452 ．

Mukherji D ， Omlin A ， Pezaro C ， et al . Metastatic castration-resistant prostate cancer（CRPC）：preclinical and clinical evidence for the sequential use of novel therapeutics [J ] . Cancer Metastasis Rev ， 2014 ， 33 （ 2/3 ）： 555 - 566 ．

Wang YY ， Chen JY ， Wu ZJ ， et al . Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it [J ] . Br J Pharmacol ， 2021 ， 178 （ 2 ）： 239 - 261 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The miR-206 inhibits proliferation，migration and invasion of prostate cancer cells by targeting PDCD10

CKLF-like MARVEL transmembrane domain-containing 6 promotes the proliferation，invasion，and migration of gastric cancer cells and inhibits apoptosis through targeted binding to human epidermal growth factor receptor 2

Effects of circular non-coding RNA hsa_circ_001842 on proliferation，apoptosis，invasion and tumorigenicity of renal cancer cells

Related Author

Zhu Huixuan

Su Shuai

Zhang Jindong

Luo Yu

Song Liangdong

Liu Hengchuan

Wang Delin

Nie Yongli

Related Institution

The Third Section of Internal Medicine，Sinopharm Hanjiang Hospital

Department of Functionology，Yangtze University

Department of Oncology，Shiyan People’s Hospital

Department of Pathology，Hubei Cancer Hospital

Department of Catheterization，The First Affiliated Hospital of Jinzhou Medical University

⁰